Abstract
Pleomorphic xanthoastrocytoma (PXA) is a rare primary CNS tumor. Recent advances in the molecular characterization are helping to define subtypes of tumor. The discovery of BRAF mutations within a substantial percentage of PXA fosters a clearer understanding of the pathophysiology of these tumors with clear prognostic and therapeutic implications. These findings are expected to provide insight into the spectrum of clinical behavior observed in PXA, ranging from cure with surgery to diffuse dissemination throughout the neuraxis. This review details the clinical presentation including radiographic appearance of PXA. Pathology, including molecular pathology is discussed. Therapeutic management including surgical resection, radiotherapy and systemic therapies are reviewed.
Cite
CITATION STYLE
Shaikh, N., Brahmbhatt, N., Kruser, T. J., Kam, K. L., Appin, C. L., Wadhwani, N., … Lukas, R. V. (2019). Pleomorphic xanthoastrocytoma: A brief review. CNS Oncology. Newlands Press Ltd. https://doi.org/10.2217/cns-2019-0009
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.